Neurogene
NGNE

$35

1.8%

Market Cap: $455M

About: Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today's complex devastating neurological diseases into treatable conditions.

Employees: 91

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

50% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 14

38% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 16

10% more funds holding

Funds holding: 60 [Q1] → 66 (+6) [Q2]

4.34% more ownership

Funds ownership: 98.41% [Q1] → 102.76% (+4.34%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

25% less capital invested

Capital invested by funds: $644M [Q1] → $485M (-$158M) [Q2]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$49

40%

upside

Avg. target

$55

56%

upside

High target

$65

86%

upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Mitchell Kapoor 49% 1-year accuracy 57 / 117 met price target	40%upside $49	Buy Maintained	12 Aug 2024
BMO Capital Keith Tapper 33% 1-year accuracy 1 / 3 met price target	86%upside $65	Outperform Initiated	27 Jun 2024
HC Wainwright & Co. Mitchell Kapoor 49% 1-year accuracy 57 / 117 met price target	46%upside $51	Buy Reiterated	20 Jun 2024
Baird Joel Beatty 51% 1-year accuracy 18 / 35 met price target	54%upside $54	Outperform Initiated	11 Jun 2024

See Analyst Rankings

Financial journalist opinion

Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced second quarter 2024 financial results and highlighted recent corporate updates. “We are pleased that NGN-401 gene therapy for Rett syndrome received RMAT designation, in addition to the recent selection by the U.S. FDA for its START Pilot Program, two programs that provide distinct opp.

Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates

Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (NASDAQ: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that NGN-401 received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for the treatment of Rett syndrome. The designation was based on preliminary clinical evidence from the ongoing Phase 1/2 clinical trial with NGN-401 that sh.

Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome

Neurogene to Participate in BMO Genetic Medicines Summit

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (NASDAQ: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the BMO 2024 Genetic Medicines Summit. Format: Management will participate in the panel, “Gene Therapy in Rare Disease: Unmet Need + Lack of Alternatives = Commercial Viability?” and participate in investor meetings Date: Tuesday, July 9 at 8.

Neurogene to Participate in BMO Genetic Medicines Summit

Neurogene Announces Addition to Russell 3000® Index

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Neurogene will be added to the Russell 3000® Index, effective at the open of U.S. equity markets today, Monday, July 1, 2024. The annual Russell indexes reconstitution captures the 4,000 largest U.S. stocks as of Tuesday, April 30, 2024, ranking them by total market capitalization.

Neurogene Announces Addition to Russell 3000® Index

Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the first patient in Cohort 2 received high-dose NGN-401 gene therapy in the Phase 1/2 trial for female pediatric patients with Rett syndrome, and high-dose NGN-401 has been well-tolerated following dosing in May 2024. The Company also provided an update on interim safety data on.

Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

Neurogene to Participate in Upcoming Conferences

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (NASDAQ: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the following conferences: Goldman Sachs 45th Annual Global Healthcare Conference Format: Management will present a corporate overview and participate in investor meetings Date: Wednesday, June 12 at 1:20 p.m. ET 2024 IRSF (International Rett.

Neurogene to Participate in Upcoming Conferences

Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (NASDAQ: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that its NGN-401 gene therapy for Rett syndrome has been selected to participate in the U.S. Food and Drug Administration (FDA) Support for Clinical Trials Advancing Rare Disease Therapeutics (START) Pilot Program. As part of the START Program, Neurogene will have opportunities for enh.

Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program

Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced first quarter 2024 financial results and highlighted recent corporate updates. “We have made substantial progress in our NGN-401 Rett syndrome gene therapy program since the beginning of the year, including dosing the third patient, expanding the trial to include additional patients an.

Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates

Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome, which showed that NGN-401 was generally well-tolerated by all three patients dosed, with follow-up of approximately nine, six and three months post-dosing. These data were pre.

Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting

Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be presented at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting. The data show that the NGN-401 gene therapy candidate has been generally well-t.

Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting

See News Rankings